{"entity":{"type":"insider","cik":"0001885327","url":"/insider/0001885327","json_url":"/insider/0001885327.json","name":"Atlas Venture Opportunity Fund II, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":33,"n_filings":8,"first":"2022-06-22","last":"2025-02-10","span_basis":"filed_date"},"name_variants":[{"name":"Atlas Venture Opportunity Fund II, L.P.","source":"filing","n_filings":8,"first_seen":"2022-06-22","last_seen":"2025-02-10"}],"transactions":[{"id":4711190,"accession":"0000950170-25-017030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-017030","line_url":"/filing/0000950170-25-017030#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Sionna Therapeutics, Inc.","issuer_ticker":"SION","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund II, L.P.","owner_display_name":"Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":1080000.0,"total_display":"1,080,000.00","total_whole":"1,080,000","shares_owned_after":807727.0,"shares_owned_after_display":"807,727","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-10","scope":"insider"},{"id":2484915,"accession":"0001415889-24-011385","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-011385","line_url":"/filing/0001415889-24-011385#line-1","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates Opportunity II, LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17857.0,"shares_display":"17,857","price_per_share":56.0,"price_display":"56.00","price_state":"stated","total_value":999992.0,"total_display":"999,992.00","total_whole":"999,992","shares_owned_after":195074.0,"shares_owned_after_display":"195,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-22","filed_date":"2024-04-23","scope":"insider"},{"id":3052919,"accession":"0001415889-24-006764","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-006764","line_url":"/filing/0001415889-24-006764","is_derivative":false,"issuer_cik":"0001759241","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001759241","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.","owner_display_name":"Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46534.0,"shares_display":"46,534","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":1398346.7,"total_display":"1,398,346.70","total_whole":"1,398,347","shares_owned_after":1458691.0,"shares_owned_after_display":"1,458,691","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider","n_lines":2},{"id":2928271,"accession":"0001415889-24-005777","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":190920.0,"shares_display":"190,920","price_per_share":24.836599622878694,"price_display":"24.84","price_state":"stated","total_value":4741803.6,"total_display":"4,741,803.60","total_whole":"4,741,804","shares_owned_after":5700521.0,"shares_owned_after_display":"5,700,521","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2928249,"accession":"0001415889-24-005777","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":368699.0,"shares_display":"368,699","price_per_share":24.405887783801962,"price_display":"24.41","price_state":"stated","total_value":8998426.42,"total_display":"8,998,426.42","total_whole":"8,998,426","shares_owned_after":5878544.0,"shares_owned_after_display":"5,878,544","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2928222,"accession":"0001415889-24-005777","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005777","line_url":"/filing/0001415889-24-005777","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LLC","owner_display_name":"Atlas Venture Associates XI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":248219.0,"shares_display":"248,219","price_per_share":23.715642033849143,"price_display":"23.72","price_state":"stated","total_value":5886672.95,"total_display":"5,886,672.95","total_whole":"5,886,673","shares_owned_after":6216250.0,"shares_owned_after_display":"6,216,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-26","filed_date":"2024-02-28","scope":"insider","n_lines":6},{"id":2659297,"accession":"0001415889-24-005124","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":196928.0,"shares_display":"196,928","price_per_share":22.7,"price_display":"22.70","price_state":"stated","total_value":4470265.6,"total_display":"4,470,265.60","total_whole":"4,470,266","shares_owned_after":6352562.0,"shares_owned_after_display":"6,352,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-23","filed_date":"2024-02-23","scope":"insider","n_lines":3},{"id":2659279,"accession":"0001415889-24-005124","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124#line-3","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":119360.0,"shares_display":"119,360","price_per_share":22.66,"price_display":"22.66","price_state":"stated","total_value":2704697.6,"total_display":"2,704,697.60","total_whole":"2,704,698","shares_owned_after":6512104.0,"shares_owned_after_display":"6,512,104","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-22","filed_date":"2024-02-23","scope":"insider"},{"id":2659275,"accession":"0001415889-24-005124","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-005124","line_url":"/filing/0001415889-24-005124","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund I, L.P.","owner_display_name":"Atlas Venture Opportunity Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":184501.0,"shares_display":"184,501","price_per_share":22.573412827030747,"price_display":"22.57","price_state":"stated","total_value":4164817.24,"total_display":"4,164,817.24","total_whole":"4,164,817","shares_owned_after":6666628.0,"shares_owned_after_display":"6,666,628","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-21","filed_date":"2024-02-23","scope":"insider","n_lines":2},{"id":2178391,"accession":"0001209191-24-002231","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-24-002231","line_url":"/filing/0001209191-24-002231","is_derivative":false,"issuer_cik":"0001628098","issuer_name":"Disc Medicine, Inc.","issuer_ticker":"IRON","issuer_name_source":null,"issuer_url":"/issuer/0001628098","owner_cik":null,"owner_name":"Atlas Venture Associates X, LLC; Atlas Venture Associates Opportunity I, L.P.; ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates Opportunity II, LLC; Atlas Venture Fund X, L.P.","owner_display_name":"Atlas Venture Associates X, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":67.65,"price_display":"67.65","price_state":"stated","total_value":10147500.0,"total_display":"10,147,500.00","total_whole":"10,147,500","shares_owned_after":703660.0,"shares_owned_after_display":"703,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider","n_lines":3},{"id":6957975,"accession":"0001209191-22-061243","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-061243","line_url":"/filing/0001209191-22-061243#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund II, L.P.","owner_display_name":"Atlas Venture Associates Opportunity II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":934581.0,"shares_display":"934,581","price_per_share":10.7,"price_display":"10.70","price_state":"stated","total_value":10000016.7,"total_display":"10,000,016.70","total_whole":"10,000,017","shares_owned_after":934581.0,"shares_owned_after_display":"934,581","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6699290,"accession":"0001209191-22-038713","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-038713","line_url":"/filing/0001209191-22-038713#line-1","is_derivative":false,"issuer_cik":"0001708269","issuer_name":"Day One Biopharmaceuticals, Inc.","issuer_ticker":"DAWN","issuer_name_source":null,"issuer_url":"/issuer/0001708269","owner_cik":null,"owner_name":"Atlas Venture Associates Opportunity I, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Associates XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Opportunity Fund II, L.P.; Atlas Venture Associates XI, LLC","owner_display_name":"Atlas Venture Associates Opportunity I, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":766667.0,"shares_display":"766,667","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":11500005.0,"total_display":"11,500,005.00","total_whole":"11,500,005","shares_owned_after":766667.0,"shares_owned_after_display":"766,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-17","filed_date":"2022-06-22","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002036042","name":"Sionna Therapeutics, Inc.","url":"/issuer/0002036042","role":"Ten percent owner","n_filings":1,"first_seen":"2025-02-10","last_seen":"2025-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Korro Bio, Inc.","url":"/issuer/0001703647","role":"Ten percent owner","n_filings":1,"first_seen":"2024-04-23","last_seen":"2024-04-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001818794","name":"Dyne Therapeutics, Inc.","url":"/issuer/0001818794","role":"Ten percent owner","n_filings":4,"first_seen":"2022-12-14","last_seen":"2024-03-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001816736","name":"Disc Medicine, Inc.","url":"/issuer/0001816736","role":"Ten percent owner","n_filings":1,"first_seen":"2024-01-25","last_seen":"2024-01-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001845337","name":"Day One Biopharmaceuticals, Inc.","url":"/issuer/0001845337","role":"Ten percent owner","n_filings":1,"first_seen":"2022-06-22","last_seen":"2022-06-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001885327","retrieved_at":"2026-08-24T16:40:09+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}